HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 270 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,564,907 | -44.6% | 48,986 | -57.0% | 0.01% | -45.5% |
Q1 2024 | $4,629,059 | -43.5% | 113,792 | -46.9% | 0.01% | -52.2% |
Q1 2023 | $8,188,853 | -73.9% | 214,424 | -61.1% | 0.02% | -76.5% |
Q4 2022 | $31,356,111 | +640.2% | 551,074 | +414.4% | 0.10% | +600.0% |
Q3 2022 | $4,236,000 | -83.1% | 107,139 | -81.2% | 0.01% | -83.1% |
Q2 2022 | $25,099,000 | +351.6% | 570,431 | +309.3% | 0.08% | +418.8% |
Q1 2022 | $5,558,000 | +25.3% | 139,362 | +27.8% | 0.02% | +60.0% |
Q3 2021 | $4,435,000 | -73.1% | 109,013 | -70.0% | 0.01% | -73.0% |
Q2 2021 | $16,488,000 | -5.0% | 363,100 | -12.8% | 0.04% | -17.8% |
Q1 2021 | $17,359,000 | +43.4% | 416,380 | +46.9% | 0.04% | +28.6% |
Q4 2020 | $12,107,000 | +8.5% | 283,471 | -33.2% | 0.04% | -12.5% |
Q3 2020 | $11,160,000 | -46.2% | 424,673 | -45.2% | 0.04% | -61.2% |
Q2 2020 | $20,758,000 | +4.4% | 774,255 | -29.9% | 0.10% | -36.4% |
Q1 2020 | $19,874,000 | -34.2% | 1,104,738 | -35.2% | 0.16% | +78.0% |
Q4 2019 | $30,222,000 | +419.5% | 1,704,582 | +354.5% | 0.09% | +355.0% |
Q3 2019 | $5,818,000 | -29.7% | 375,083 | -22.1% | 0.02% | -28.6% |
Q2 2019 | $8,271,000 | +2347.0% | 481,418 | +2196.4% | 0.03% | +2700.0% |
Q1 2019 | $338,000 | -44.7% | 20,964 | -49.8% | 0.00% | -50.0% |
Q4 2018 | $611,000 | -92.9% | 41,746 | -91.1% | 0.00% | -91.3% |
Q3 2018 | $8,557,000 | +24.4% | 470,966 | +15.5% | 0.02% | +9.5% |
Q2 2018 | $6,877,000 | -68.5% | 407,656 | -63.5% | 0.02% | -71.2% |
Q1 2018 | $21,862,000 | +3.6% | 1,115,986 | +7.1% | 0.07% | +5.8% |
Q4 2017 | $21,104,000 | +55.4% | 1,041,676 | +33.3% | 0.07% | +43.8% |
Q3 2017 | $13,578,000 | +170.6% | 781,691 | +99.7% | 0.05% | +166.7% |
Q2 2017 | $5,018,000 | +1606.8% | 391,412 | +2207.7% | 0.02% | +1700.0% |
Q4 2015 | $294,000 | -89.6% | 16,961 | -92.0% | 0.00% | -92.9% |
Q3 2015 | $2,830,000 | +1308.0% | 210,719 | +2272.2% | 0.01% | +1300.0% |
Q2 2015 | $201,000 | – | 8,883 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |